Get the Stockscreener App
3.43
5.54%
0.18
After Hours:
3.29
-0.14
-4.08%
Biodexa Pharmaceuticals Plc Adr stock is traded at $3.43, with a volume of 57,490.
It is up +5.54% in the last 24 hours and down -17.45% over the past month.
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
See More
Previous Close:
$3.25
Open:
$3.25
24h Volume:
57,490
Relative Volume:
0.13
Market Cap:
$2.22M
Revenue:
$104.00K
Net Income/Loss:
$-8.39M
P/E Ratio:
-0.033
EPS:
-103.9477
Net Cash Flow:
$-8.31M
1W Performance:
-2.28%
1M Performance:
-17.45%
6M Performance:
-91.54%
1Y Performance:
-95.30%
1-Day Range:
$3.20
$3.43
1-Week Range:
$2.86
$3.43
52-Week Range:
$2.86
$96.50
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Company Profile
Name
Biodexa Pharmaceuticals Plc Adr
Sector
Industry
Phone
-
Address
-
Compare BDRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BDRX
Biodexa Pharmaceuticals Plc Adr
|
3.43 | 2.11M | 104.00K | -8.39M | -8.31M | -103.95 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-08-24 | Initiated | Ladenburg Thalmann | Buy |
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Latest News
Inventory turnover of Biodexa Pharmaceuticals plc Sponsored ADR – FWB:5MP2 - TradingView — Track All Markets
Net income before discontinued operations of Biodexa Pharmaceuticals plc Sponsored ADR – FWB:5MP2 - TradingView — Track All Markets
Book value per share of Biodexa Pharmaceuticals plc Sponsored ADR – FWB:5MP2 - TradingView — Track All Markets
Biodexa Pharmaceuticals plc Sponsored ADR Cash Flow – FWB:5MP2 - TradingView — Track All Markets
Net debt of Biodexa Pharmaceuticals plc Sponsored ADR – FWB:5MP2 - TradingView
Basic earnings per share (basic EPS) of Biodexa Pharmaceuticals plc Sponsored ADR – FWB:5MP2 - TradingView
Who's Buying or Selling Biodexa Pharmaceuticals PLC (STU:5MP2) Stock Today? - GuruFocus
Biodexa Pharmaceuticals Plc: Shareholders Board Members Managers and Company Profile | US59564R8723 - marketscreener.com
Why Is Biodexa Pharmaceuticals (BDRX) Stock Skyrocketing Today? - Sahm
Why is Biodexa Pharmaceuticals (BDRX) stock skyrocketing today? - MSN
Biodexa partners with Syngene for MTX240 manufacturing By Investing.com - Investing.com Australia
171.7M Ordinary Shares resale prospectus — Biodexa (NASDAQ: BDRX) - Stock Titan
109.8M Ordinary Shares resale prospectus — Biodexa (NASDAQ: BDRX) - stocktitan.net
943.4M Ordinary Shares for Resale; Biodexa (NASDAQ: BDRX) resale filing - stocktitan.net
1.7018B shares for resale by holders — Biodexa (NASDAQ: BDRX) - Stock Titan
Biodexa Pharmaceuticals (NASDAQ: BDRX) registers 2.99M ADS for resale via equity line - Stock Titan
Biodexa’s eRapa Program: Global Expansion and European Gains - StocksToTrade
Biodexa partners with Syngene for MTX240 manufacturing - Investing.com
Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies - ChartMill
BDRX SEC FilingsBiodexa Pharmaceuticals plc 10-K, 10-Q, 8-K Forms - Stock Titan
No approved FAP drug: Biodexa opens global eRapa access - Stock Titan
[EFFECT] Biodexa Pharmaceuticals Plc SEC Filing - Stock Titan
Biodexa Pharmaceuticals (NASDAQ: BDRX) registers 2.99M ADSs for resale under equity line - Stock Titan
943.4M Ordinary Shares resale by selling holders (NASDAQ: BDRX) - Stock Titan
Biodexa Pharmaceuticals (BDRX) flags going-concern doubts amid ongoing losses - Stock Titan
Biodexa (NASDAQ: BDRX) grows pipeline but warns on 2026 funding needs - stocktitan.net
Preliminary Results for the Year Ended 31 December 2025 - GlobeNewswire
Biodexa partners with Tanner Pharma for FAP drug early access By Investing.com - Investing.com Australia
Biodexa Launches Global Early Access Program for eRapa for - GlobeNewswire
Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group - markets.businessinsider.com
Biodexa partners with Tanner Pharma for FAP drug early access - Investing.com
Biodexa (NASDAQ: BDRX) director reports detailed stock option holdings - stocktitan.net
Biodexa Pharmaceuticals changes ADR ratio to meet Nasdaq rules By Investing.com - Investing.com Australia
Biodexa Pharmaceuticals announces ADR ratio change - MSN
Biodexa Pharmaceuticals Announces Reverse ADR Split to Support Nasdaq Compliance - tipranks.com
Biodexa Pharmaceuticals (BDRX) Announces ADR Ratio Change - GuruFocus
Biodexa Pharmaceuticals changes ADR ratio to meet Nasdaq rules - Investing.com
Biodexa Pharmaceuticals PLC Announces ADR Ratio Change to Comply with Nasdaq Minimum Bid Price Requirement - Quiver Quantitative
Reverse ADR split at Biodexa (Nasdaq: BDRX) targets Nasdaq $1 bid rule - Stock Titan
ADR Ratio Change - Bitget
Biodexa Pharmaceuticals (NASDAQ: BDRX) director lists stock option position - Stock Titan
Biodexa (NASDAQ: BDRX) CEO lists detailed stock option holdings - Stock Titan
Biodexa Pharmaceuticals (NASDAQ: BDRX) director details ADS option stake - Stock Titan
Biodexa (BDRX) CFO details multi-year stock option grants - Stock Titan
Biodexa Pharmaceuticals (BDRX) director Simon Turton reports initial equity holdings - Stock Titan
Biodexa Announces Support for Life’s a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients - ChartMill
New U.S. group for those facing near-100% colon cancer risk, backed by Biodexa - Stock Titan
BDRXBiodexa Pharmaceuticals plc Latest Stock News & Market Updates - Stock Titan
Biodexa Pharmaceuticals (NASDAQ:BDRX) Upgraded at Wall Street Zen - Defense World
Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer - Finviz
New molecular glue drug aims to tackle deadly stomach tumors - Stock Titan
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):